PP1493

AXP000229.1 · Phage therapy

Platform
single phage, solution for injection
Originator
Pherecydes Pharma
Sponsor
Phaxiam Therapeutics

Names

NameTypeSource
PP1493preferred name, codecurator, curator

Virus

Role
Phage
Family
Caudoviricetes
Virus
Staphylococcus aureus bacteriophage
Replication
replicating
Route
intravenous, inhaled
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06605651Proof of Concept Study to Assess Safety and Efficacy of Phage Therapy in Hip or Knee Prosthetic Joint Infections Due to Staphylococcus Aureus Treated by DAIR.Not yet recruitingPhase 22026-072028-03100Hip Prosthesis Infection; Knee Prosthesis Infection

Recent changes

No changes recorded in its trials yet.

Notes

Anti-Staphylococcus aureus phage, supplied as a solution for injection and used with PP1815 under French compassionate access (ANSM) for bone and joint infection, intravenously for bacteraemia and endocarditis and by aerosol for purulent bronchopathy, and in the PhagoDAIR I trial NCT05369104 (EudraCT 2021-004469-11) and PhagoDAIR II NCT06605651. Entered separately from PP1815 because the two are separate injectable products that a phagogram can find active singly or together.

How to cite

PP1493 (AXP000229.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000229.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.